Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company’s proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
50.0%
招募中
1
50.0%
暂无批准数据
- Turn Therapeutics' Phase 2 randomized controlled trial of GX-03, a first-in-class IL-36/IL-31 pathway inhibitor for moderate-severe atopic dermatitis, remains on track with both interim analysis and topline data expected in the first half of 2026. - The company has expanded its vaccine pipeline to include an intranasal influenza candidate that leverages proprietary delivery technology to potentially stimulate systemic immunity without adjuvants or harmful additives. - Turn Therapeutics strengthened its board with the appointment of Martin Dewhurst, a 30+ year McKinsey veteran, and expects revenue generation in 2026 through its strategic partnership with Medline in the advanced wound care market. - The company's operational runway extends into late 2026 following recent capital strengthening activities, positioning it for clinical readouts and commercial execution.
- Turn Therapeutics, a clinical-stage biotechnology company, expects to begin trading on Nasdaq Global Market under ticker "TTRX" on October 8, 2025. - The company has received three FDA clearances for proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis. - Turn is pursuing global health initiatives in thermostable vaccine delivery designed to serve underserved areas worldwide. - The company hosted an open investor session on September 17 in connection with its Form S-1 registration statement filing for the proposed public listing.
- Turn Therapeutics has begun a randomized, double-blind, vehicle-controlled clinical trial evaluating topical GX-03 formulation for moderate-to-severe eczema treatment, marking the first clinical trial of a topical IL-36 inhibitor. - The phase 1/2 study aims to enroll 114 patients with an eight-week treatment course, with primary endpoint measuring changes in Eczema Area and Severity Index (EASI) scores from baseline. - GX-03 demonstrates potent immunological inhibition of key eczema-related cytokines including IL-36 alpha, IL-31, IL-4, and IL-36 gamma, with over 200,000 human uses establishing its safety profile. - Top-line results are expected by end of 2025, potentially offering a novel non-steroidal therapeutic alternative to current systemic or corticosteroid-based therapies for eczema patients.
- Turn Therapeutics has demonstrated 100% recovery of vesicular stomatitis virus (VSV) after 72 hours in an oil-based carrier at room temperature, potentially eliminating cold storage requirements for vaccines. - The breakthrough, developed in partnership with the International AIDS Vaccine Initiative, represents the first successful quantitative recovery of a live virus stably suspended in an oil-based carrier. - This technology could revolutionize vaccine distribution to remote and low-resource settings by extending viability from four hours to at least 72 hours without refrigeration.
- Turn Therapeutics' GX-03 demonstrated significant inhibition of IL-31, IL-36α, and IL-36γ in a preclinical eczema model, suggesting potential efficacy in atopic dermatitis. - The study showed a 67.7% reduction in IL-31 levels compared to placebo (p < 0.000001), highlighting GX-03's ability to modulate key cytokines involved in eczema pathogenesis. - GX-03 pretreatment led to a significant reduction in ISGA score, indicating a shift from mild-moderate eczema to clear or almost clear skin compared to placebo. - With a well-established safety profile, Turn Therapeutics plans to advance GX-03, a non-steroid, non-injectable asset, into clinical trials for atopic dermatitis.
